Clear Search sequence regions


  • alleles (6)
  • DOCK4 (1)
  • dock4 protein, human (1)
  • EGFR (3)
  • genes (5)
  • genomes (1)
  • germ cells (1)
  • gtpase (2)
  • human (2)
  • odds ratio (1)
  • patients (1)
  • protein human (1)
  • receptors (2)
  • synapse (1)
  • Sizes of these terms reflect their relevance to your search.

    Cancer is a disease driven by a combination of inherited risk alleles coupled with the acquisition of somatic mutations, including amplification and deletion of genomic DNA. Potential relationships between the inherited and somatic aspects of the disease have only rarely been examined on a genome-wide level. Applying a novel integrative analysis of SNP and copy number measurements, we queried the tumor and normal-tissue genomes of 178 glioblastoma patients from the Cancer Genome Atlas project for preferentially amplified alleles, under the hypothesis that oncogenic germline variants will be selectively amplified in the tumor environment. Selected alleles are revealed by allelic imbalance in amplification across samples. This general approach is based on genetic principles and provides a method for identifying important tumor-related alleles. We find that SNP alleles that are most significantly overrepresented in amplicons tend to occur in genes involved with regulation of kinase and transferase activity, and many of these genes are known contributors to gliomagenesis. The analysis also implicates variants in synapse genes. By incorporating gene expression data, we demonstrate synergy between preferential allelic amplification and expression in DOCK4 and EGFR. Our results support the notion that combining germline and tumor genetic data can identify regions relevant to cancer biology.

    Citation

    Thomas LaFramboise, Ninad Dewal, Katherine Wilkins, Itsik Pe'er, Matthew L Freedman. Allelic selection of amplicons in glioblastoma revealed by combining somatic and germline analysis. PLoS genetics. 2010 Sep 02;6(9):e1001086

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 20824129

    View Full Text